According to the American Kennel Club (AKC),3 small dog breeds, such as the Cocker Spaniel, are commonly known to develop congestive heart failure due to mitral valve issues. Owners of dogs suffering from congestive heart failure now have a liquid treatment option to manage the disease. VETMEDIN Solution (pimobendan oral solution) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of congestive heart failure (CHF) in dogs due to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). Manufactured by Boehringer Ingelheim, the flavorless, twice-daily liquid oral solution is reported to have helped increase the survival time and quality of life in dogs due to MMVD or DCM.1,2 “We know some dogs and pet owners may prefer a liquid medication, especially for smaller dogs,” says Daniel Watkins, VP, US Pet Business, Boehringer Ingelheim. “With VETMEDIN® Solution, an easy-to- use liquid formulation, we can help more dogs with heart disease have longer survival and live better lives.” VETMEDIN is also available in chewable tablets. For more information, visit the Boehring Ingelheim website. References Häggström, J et al. “Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.” Journal of Veterinary Internal Medicine vol. 27,6 (2013): 1441-51. doi:10.1111/jvim.12181 Lombard, Christophe W et al. “Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.” Journal of the American Animal Hospital Association vol. 42,4 (2006): 249-61. doi:10.5326/0420249 https://www.akc.org/expert-advice/health/congestive-heart-failure-in-dogs-what-you-need-to-know/
